{"id":"W4410817483","doi":"10.1200/jco.2025.43.16_suppl.e15113","title":"Efficacy and safety data from Ph1b, dose optimization trial of two doses of TH1902 (sudocetaxel zendusortide), a novel SORT1-targeting peptide drug conjugate (PDC), administered weekly vs q3weekly in patients (pts) with advanced ovarian cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Theratechnologies (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Conjugate; Pharmacology; Drug; Safety profile; Peptide; Clinical trial; Oncology; Internal medicine; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006851302,0.0007250282,0.0008642611,0.0002690137,0.0002534256,0.0005896251,0.0004384178,0.0009567062,0.003597638],"category_scores_gemma":[0.0006826773,0.00034147,0.0007552473,0.0002252937,0.0005527299,0.0005410698,0.0002430539,0.002130973,0.0006125602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007260169,"about_ca_system_score_gemma":0.0006590409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006688643,"about_ca_topic_score_gemma":0.001363387,"domain_scores_codex":[0.999765,0.00008724895,0.0000141303,0.00005556919,0.00002674156,0.00005137403],"domain_scores_gemma":[0.9995344,0.000102183,0.0001131182,0.00003762055,0.00002631638,0.00018646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8101565,0.04678258,0.006628637,0.0003965937,0.0005631698,0.0002025892,0.0002084535,0.002272973,0.05792454,0.0001803771,0.002648014,0.07203566],"study_design_scores_gemma":[0.2370827,0.7233269,0.02472291,0.00002762874,0.0003843492,0.0002575312,0.00004140451,0.001066225,0.01010361,0.0001450352,0.00281319,0.00002857387],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957495,0.0008001403,0.0002301169,0.00015157,0.00003568989,0.0007042597,0.0009142926,0.00002960486,0.001384769],"genre_scores_gemma":[0.9947906,0.0004465358,0.000393257,0.0003086663,0.00006340065,0.0005861203,0.001526911,0.0000107926,0.001873744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003597638,"threshold_uncertainty_score":0.01203531,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.107380014989888,"score_gpt":0.4632576445412748,"score_spread":0.3558776295513867,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}